Fusion Antibodies (LON:FAB) Trading Up 2.3% – Still a Buy?

Fusion Antibodies plc (LON:FAB)’s share price traded up 2.3% on Wednesday . The company traded as high as GBX 4.30 ($0.05) and last traded at GBX 4.30 ($0.05). 353,922 shares were traded during mid-day trading, a decline of 66% from the average session volume of 1,047,788 shares. The stock had previously closed at GBX 4.20 ($0.05).

Fusion Antibodies Stock Up 35.7 %

The company has a market cap of £5.44 million, a price-to-earnings ratio of -107.43 and a beta of 0.49. The company has a debt-to-equity ratio of 2.40, a quick ratio of 2.36 and a current ratio of 3.87. The stock’s fifty day moving average is GBX 4.26 and its two-hundred day moving average is GBX 3.65.

Insider Transactions at Fusion Antibodies

In other Fusion Antibodies news, insider Richard John Buick bought 94,825 shares of Fusion Antibodies stock in a transaction dated Monday, September 9th. The stock was bought at an average cost of GBX 3 ($0.04) per share, with a total value of £2,844.75 ($3,604.60). Also, insider Adrian Kinkaid purchased 83,728 shares of the company’s stock in a transaction that occurred on Wednesday, October 16th. The shares were acquired at an average price of GBX 4 ($0.05) per share, for a total transaction of £3,349.12 ($4,243.69). Company insiders own 11.39% of the company’s stock.

About Fusion Antibodies

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services.